News | Atrial Fibrillation | February 09, 2023

Clinical Study Shows Cardiomatics AI Technology is Accurate Tool for Assessment of Atrial Fibrillation

The research conducted by the University Hospital Basel in Switzerland aimed to explore the association between the AF burden and its health consequences 

The research conducted by the University Hospital Basel in Switzerland aimed to explore the association between the AF burden and its health consequences

February 9, 2023 — The Cardiomatics certified online SaaS platform provides world-class Holter ECG analytics to support cardiac care. Its advanced algorithms have been validated in various clinical trials and used commercially by hundreds of cardiologists and general practitioners from over 15 countries around the world, including Germany, Switzerland, Poland and the United Kingdom.  

In the latest Swiss-AF Burden Study conducted by the Swiss University Hospital Basel in Switzerland, Cardiomatics’ state-of-the-art technology was implemented to analyze signals from 7-day Holter-ECG recordings and ensure the highest-quality analysis. The study included 100 Holter recordings from patients who suffered from paroxysmal or persistent AF. Researchers compared the results of a traditional Holter ECG analysis with those of an automated Cardiomatics analysis and showed that assessment of the AF burden with AI algorithms provided very similar results to standard assessment (Pearson’s correlation coefficient: 0.998). The Bland-Altman analysis resulted in a bias of -0.006 (95% limits of agreement -0.042 to 0.030). Hence, Cardiomatics’ innovative technology is an accurate and efficient method for the assessment of the AF burden.  

“During our research, we were able to compare the results of our team's manual analysis and the automated analysis provided by Cardiomatics. Our recent study enabled us to discover the potential of AI algorithms and confirmed their high precision,” said Prof. Michael Kühne, MD from the University Hospital Basel in Switzerland.  

Despite the evidence currently available on the association between AF, stroke, and systemic embolism, the underlying mechanisms are still largely unknown. Moreover, therapy increasingly requires personalization and an individual approach to each patient. Thus, implementing new technologies such as AI algorithms can accelerate the diagnostic process and reduce physicians’ workload without compromising data quality. The study showed that artificial intelligence can truly complement the knowledge and experience of doctors to enhance diagnostic capabilities and improve treatment outcomes. 

“The data confirm that artificial intelligence is an accurate and reliable tool that can support physicians in long-term ECG analysis. Cardiomatics software is not only precise, but as it turned out during our research, it enables us to analyse ECG signals significantly faster compared to manual analysis. At the same time, we get high-quality data and reports. Using AI in clinical practice is an opportunity for cardiologists to reduce time spent on manual ECG analysis and examine more patients who need cardiac care,”said Prof. Christine Meyer-Zürn, MD from the University Hospital Basel, Switzerland. 

More and more doctors are deciding to rely on artificial intelligence tools for Holter ECG analysis. The number of Cardiomatics customers is constantly growing not only among commercial users, but also among researchers. Beyond the presented study, Cardiomatics has already started new clinical trials with the University Hospital Basel in Switzerland and other research centers, such as Weill Cornell Medicine in the USA. When it comes to commercial users, the greatest interest in Cardiomatics’ solution originates from private practice and clinics in Switzerland. The most significant advantages of the cutting-edge software mentioned by Swiss physicians are its ease of use, its accuracy and the time it saves compared to manual analysis. In a long-term perspective, it enables them to reduce their workload, examine more patients without having to increase staff numbers, perform a larger number of long-term ECGs and make more precise diagnoses much more quickly.  

“We are proud that implementing Cardiomatics software in the Swiss AF Burden Study significantly improved the complex research process. It is amazing that we can so easily optimize the daily work of doctors, both for scientific purposes and in everyday medical practice. Our hardware independence, ease of integration and user-friendly platform make it effortless to deploy Cardiomatics in both hospitals and private practice. After that, medical facilities and patients can only reap business and health benefits,” said Nikola Fajkis-Zajączkowska, Clinical Project Manager at Cardiomatics.  

For more information: www.cardiomatics.com


Related Content

News | Atrial Fibrillation

March 9, 2023 — People with a recent diagnosis of atrial fibrillation (AF), the most common irregular heart rhythm, have ...

Home March 09, 2023
Home
News | Atrial Fibrillation

March 8, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home March 08, 2023
Home
News | Atrial Fibrillation

March 6, 2023 — A new ablation technology known as pulsed field ablation was successful at eliminating episodes of ...

Home March 06, 2023
Home
News | Atrial Fibrillation

February 14, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home February 14, 2023
Home
News | Atrial Fibrillation

February 6, 2023 — In the largest genetic study of heart arrhythmia to date, researchers led by Kazuo Miyazawa and Kaoru ...

Home February 06, 2023
Home
News | Atrial Fibrillation

February 2, 2023 — Abbott today announced two approvals as part of its growing suite of electrophysiology products in ...

Home February 02, 2023
Home
News | Atrial Fibrillation

February 1, 2023 — Periodontitis, a gum disease, can lead to a litany of dental issues from bad breath to bleeding and ...

Home February 01, 2023
Home
News | Atrial Fibrillation

December 14, 2022 — Field Medical, Inc. and CardioNXT, Inc. announce a strategic collaboration to provide the first-of ...

Home December 14, 2022
Home
News | Atrial Fibrillation

November 10, 2022 — Biosense Webster, Inc., the global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home November 10, 2022
Home
News | Atrial Fibrillation

November 10, 2022 — A national study led by UBC researchers at the Centre for Cardiovascular Innovation is shedding ...

Home November 10, 2022
Home
Subscribe Now